Storandt M - Search Results

1

Rates of progression in mild cognitive impairment and early Alzheimer's disease.

Storandt M, Grant EA, Miller JP, Morris JC. Storandt M, et al. Neurology. 2002 Oct 8;59(7):1034-41. doi: 10.1212/wnl.59.7.1034. Neurology. 2002. PMID: 12370458

2

Clinical outcomes of possible versus probable Alzheimer's disease.

Villareal DT, Grant E, Miller JP, Storandt M, McKeel DW, Morris JC. Villareal DT, et al. Among authors: storandt m. Neurology. 2003 Sep 9;61(5):661-7. doi: 10.1212/wnl.61.5.661. Neurology. 2003. PMID: 12963758

3

Absence of effect of depression on cognitive performance in early-stage Alzheimer disease.

Powlishta KK, Storandt M, Mandernach TA, Hogan E, Grant EA, Morris JC. Powlishta KK, et al. Among authors: storandt m. Arch Neurol. 2004 Aug;61(8):1265-8. doi: 10.1001/archneur.61.8.1265. Arch Neurol. 2004. PMID: 15313845

4

Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study.

Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC. Galvin JE, et al. Among authors: storandt m. Arch Neurol. 2005 May;62(5):758-65. doi: 10.1001/archneur.62.5.758. Arch Neurol. 2005. PMID: 15883263

5

Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI.

Storandt M, Grant EA, Miller JP, Morris JC. Storandt M, et al. Neurology. 2006 Aug 8;67(3):467-73. doi: 10.1212/01.wnl.0000228231.26111.6e. Neurology. 2006. PMID: 16894109

6

Clinical and psychometric distinction of frontotemporal and Alzheimer dementias.

Liscic RM, Storandt M, Cairns NJ, Morris JC. Liscic RM, et al. Among authors: storandt m. Arch Neurol. 2007 Apr;64(4):535-40. doi: 10.1001/archneur.64.4.535. Arch Neurol. 2007. PMID: 17420315

7

Longitudinal study of the transition from healthy aging to Alzheimer disease.

Johnson DK, Storandt M, Morris JC, Galvin JE. Johnson DK, et al. Among authors: storandt m. Arch Neurol. 2009 Oct;66(10):1254-9. doi: 10.1001/archneurol.2009.158. Arch Neurol. 2009. PMID: 19822781 Free PMC article.

8

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Morris JC, et al. Among authors: storandt m. Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269. Arch Neurol. 2009. PMID: 20008650 Free PMC article.

9

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

Storandt M, Mintun MA, Head D, Morris JC. Storandt M, et al. Arch Neurol. 2009 Dec;66(12):1476-81. doi: 10.1001/archneurol.2009.272. Arch Neurol. 2009. PMID: 20008651 Free PMC article.

10

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Cairns NJ, et al. Among authors: storandt m. Arch Neurol. 2009 Dec;66(12):1557-62. doi: 10.1001/archneurol.2009.279. Arch Neurol. 2009. PMID: 20008664 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters